MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in Patients With Progressive Metastatic Cutaneous Melanoma

Melanoma Clinical Trial

Official title:

Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00706238
• Other study ID #: 110551
• Secondary ID: 2007-005203-18
• Status: Terminated
• Phase: Phase 2
• Start date: September 29, 2008
• Est. completion date: January 19, 2011

Study information

• Verified date: September 2020
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is being done to evaluate the safety and the clinical activity of MAGE-A3 Antigen-Specific Cancer Immunotherapeutic in patients with unresectable and progressive metastatic cutaneous melanoma.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: January 19, 2011
• Est. primary completion date: January 19, 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patient with histologically proven, measurable metastatic cutaneous melanoma, and with documented progressive disease within the 12 weeks before the first administration of study treatment.

• Written informed consent has been obtained from the patient before the performance of any protocol-specific procedure.

• Patient is >= 18 years of age at the time of signature of the informed consent.

• The patient's tumor shows expression of MAGE-A3 gene

• ECOG performance status of 0 or 1.

• The patient has normal organ functions

• If the patient is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to administration of study treatment, have a negative pregnancy test and continue such precautions during all study treatment period and for 2 months after completion of the injection series.

• In the view of the investigator, the patient can and will comply with the requirements of the protocol.

Exclusion Criteria:

• The patient has at any time received systemic (bio-)chemotherapy (except for isolated limb perfusion, as long as this was performed at least 4 weeks before first study treatment administration).

• The patient is scheduled to receive any anti-cancer specific treatment, including radiotherapy, immunotherapy, chemotherapy and immunomodulating agents.

• The patient requires concomitant treatment with systemic corticosteroids, or any other immunosuppressive agents.

• The patient received any cancer immunotherapeutic containing a MAGE-A3 antigen or any cancer immunotherapeutic for his/her metastatic disease.

• The patient has received any investigational or non-registered drug or vaccine other than the study medication within the 30 days preceding the first ASCI injection or it is planned that (s)he will receive such a drug during the study period.

• The patient has (or has had) previous or concomitant malignancies at other sites, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.

• History of allergic disease or reactions likely to be exacerbated by any component of the study investigational product.

• The patient has an autoimmune disease such as, but not limited to, multiple sclerosis, lupus, and inflammatory bowel disease. Patients with vitiligo are not excluded.

• The patient has a family history of congenital or hereditary immunodeficiency.

• The patient is known to be positive for the Human Immunodeficiency Virus (HIV).

• The patient has psychiatric or addictive disorders that may compromise his/her ability to give informed consent, or to comply with the trial procedures.

• The patient has concurrent severe medical problems, unrelated to the malignancy, that would significantly limit full compliance with the study or expose the patient to unacceptable risk.

• For female patients: the patient is pregnant or lactating.

Related Conditions & MeSH terms

• Melanoma

Intervention

Biological:
• GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A
IM administration in the deltoid or lateral regions of the thighs, alternately on the right and left sides.

Locations

Country	Name	City	State
Argentina	GSK Investigational Site	Caba	Buenos Aires
Argentina	GSK Investigational Site	Quilmes	Buenos Aires
Argentina	GSK Investigational Site	Rosario	Santa Fe
Greece	GSK Investigational Site	Athens
Greece	GSK Investigational Site	Athens
Norway	GSK Investigational Site	Oslo

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Argentina,  Greece,  Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Subjects With Any Antigen-Specific Cancer Immunotherapeutic (ASCI) Related Grade 3/4 Adverse Events (AE)	The assessment was made as per the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, where Grade refers to the severity of the AE. The CTCAE version 3.0 displays Grades 1 through 5 with unique clinical descriptions of severity for each AE, as follows: Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE.	During the entire study, up to 2.5 years per patient
Primary	Number of Subjects With Any Serious Adverse Events (SAEs).	SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.	During the entire study, up to 2.5 years per patient
Primary	The Rate of Objective Clinical Response.		At the time of analysis.
Secondary	The Rate of Stable Disease.		At the time of analysis.
Secondary	The Rate of Mixed Response.		At the time of analysis.
Secondary	Time to Study Treatment Failure.		At the time of analysis.
Secondary	Progression-free Survival.		At the time of analysis.
Secondary	Progression-free Survival After Initial SPD.		At the time of analysis.
Secondary	Documentation of Any Toxicity.		During the entire study, up to 2.5 years per patient
Secondary	Immunogenicity at Defined Time Points.		At 13 defined time points.